A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ — Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, ...

Immorta Bio Inc, a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease" announced today results of laboratory experiments, covered in newly filed patent ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

Senti Biosciences, Inc.’s SNTI share price has surged by 5.44%, which has investors questioning if this is right time to sell.

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology (ASCO), ...

A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as ...

NK cell therapy is fast developing into a busy field, so it's something of a coup for Shoreline to forge an alliance with an established player like Gilead/Kite.

The AERIAL trial will assess LEU011, which has MHRA Innovation Passport status, for solid tumors, a challenging area compared ...

Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains on what looks like ...